58 results
Selected Clinical Trials of SGLT2 inhibitors in CVD and CKD
EMPA-REG OUTCOME - Empagliflozin lowered CV events
and CKD EMPA-REG OUTCOME ... T2DM; first renal outcomes ... Dapagliflozin improved HF outcomes ... Empagliflozin improved HF outcomes ... visualabstract #table
Cerebral Venous Thrombosis (CVT) - Management Algorithm
Prognostic score for CVT:
Variables: Malignancy 2, Coma 2, Deep venous
) - Management Algorithm ... Low risk of poor outcome ... High risk of poor outcome ... Thrombosis #Management #Algorithm
Management of adult IgA Vasculitis (Henoch-Schönlein purpura) - Treatment algorithm for the management of IgAV patients
purpura) - Treatment algorithm ... the long-term outcome ... improved long-term outcome ... Rheumatology #Vasculitis #Algorithm
Diabetes Medications Summary Table
Insulin
Lifestyle modifications
Metformin
Sulfonylureas
GLP-1 receptor agonists - ↓ major adverse CV events
TZDs
DPP-4 inhibitors
SGLT2 inhibitors -
Medications Summary Table ... events, Improved outcomes ... #medications #table
Global Alliance algorithm to improve outcomes in acne.
†With small nodules (>0.5–1 cm).
‡Consider physical removal of comedones.
§Second
Global Alliance algorithm ... to improve outcomes ... Second course in case ... Acne #Treatment #Algorithm
Summary of meta-analysis of pharmacotherapy trials in BPD
https://www.cochrane.org/CD005652/BEHAV_psychological-therapies-borderline-personality-disorder
Meta-analyses of RCTs were undertaken for the following outcomes:
the following outcomes ... mental state outcomes ... summarised in Tables ... Effectiveness #Table
The rationale for aggressive treatment of generalized status epilepticus was described previously here.  In short,
In short, best outcomes ... epilepticus which may cause ... epilepticus may cause ... Refractory #Seizures #Algorithm
NS vs Balanced Solutions - Comparison of clinical outcomes. 
#EBM #Nephrology #Saline #Balanced #Fluids #Trials #Comparison
Comparison of clinical outcomes ... Trials #Comparison #Table ... #Outcomes
TOPCAT - Spironolactone for Heart Failure with Preserved Ejection Fraction

N Engl J Med 2014; 370:1383-1392 https://www.nejm.org/doi/10.1056/NEJMoa1313731

CONCLUSIONS:
primary composite outcome ... cardiovascular causes
GLP-1 Receptor Agonists - Pharmacology Summary
Mechanisms of Action: Stimulate glucose-dependent insulin release from the pancreas (GLP-1
Ozempic), or daily tablet ... of adverse CV outcomes ... e.g. diarrhea, nausea ... not definitively cause